An observational study in Spinal Tumor, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Peking University Third Hospital · Observational
Among 14 studies in Spinal Cord Neoplasms with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Spinal Cord Neoplasms · China.
Among the 14 studies in Spinal Cord Neoplasms with a site in China, this one is the only one that started in 2017, is one of 8 observational ones, and was the 11th registered.
105 studies on the registry are indexed under Spinal Cord Neoplasms; 27 are open to participants now.
Browse Spinal Cord Neoplasms studies →7 of the 14 studies in Spinal Cord Neoplasms with a site in China are open now. Recruiting first, the newest first:
Wei Xu · Sites in China
Ages 18+
Shanghai Changzheng Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Shengjing Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 3–75
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 23 Spinal Cord Neoplasms studies recruiting now, 15 (65%) set no upper age limit and 5 (22%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 150 across 31 observational studies indexed under Spinal Cord Neoplasms.
Median enrollment 103 across the 6 interventional studies, 125 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
Peking University Third Hospital is the lead sponsor of 752 studies on the registry; 273 are open to participants now.
Peking University Third Hospital has 4 studies filed under Spinal Cord Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Spinal Cord Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06587022Peking University Third HospitalDelineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors | 2026-12-30 |
| NCT07066475Beijing Tiantan HospitalA Registry-Based Cohort Study on the Clinical Outcomes of Spinal Cord Glioma Resection Via the Dorsolateral Sulcus Approach | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Spinal Cord Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.
The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors. This is a bidirectional cohort study planned to enroll approximately 500 patients with metastatic spinal tumors. Patients are divided into two groups according to the target delineation method. Group 1：The target bolume only includes local tumor. Group 2：The target bolume includes local tumor and adjacent vertebral area.
Patients with malignant tumor spinal metastasis who received or will receive stereotactic radiotherapy, without preoperation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group 1(small target delineation)：The target bolume only includes local tumor.
Radiation: Target volume delineation
Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
Radiation: Target volume delineation
Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
Disease Control Rate（DCR）
Disease Control Rate（DCR），including complete response（CR），partial response(PR) and stable disease(SD ).
Time frame: 2 years
Pain relief rate
VAS Score(Visual Analog Scale Score) decreased after treatment
Time frame: 3 months
Incidence of side effects
radiation myelitis,radiation esophagitis, etc.
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2017 (actual). Primary completion is estimated for Dec 2026, 119 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital →